close
close

Metagenomi Reports Business Updates and Financial Results for the Second Quarter of 2024

Posted on by Vaseline
Metagenomi Reports Business Updates and Financial Results for the Second Quarter of 2024

Designated development candidate MGX-001 for the treatment of hemophilia A;
plans to present 12-month NHP sustainability data in September 2024

All Wave 1 Ionis partnership programs are making progress in lead optimization, creating the potential for multiple development candidate nominations in 2025

Related Posts